The Dementia with Lewy Bodies (DLB) Consortium has refined its recommendations about the clinical and pathologic diagnosis of DLB, updating the previous report, which has been in widespread use for the last decade. The revised DLB consensus criteria now distinguish clearly between clinical features and diagnostic biomarkers, and give guidance about optimal methods to establish and interpret these. Substantial new information has been incorporated about previously reported aspects of DLB, with increased diagnostic weighting given to REM sleep behavior disorder and 123iodine-metaiodobenzylguanidine (MIBG) myocardial scintigraphy. The diagnostic role of other neuroimaging, electrophysiologic, and laboratory investigations is also described. Minor modifications to pathologic methods and criteria are recommended to take account of Alzheimer disease neuropathologic change, to add previously omitted Lewy-related pathology categories, and to include assessments for substantia nigra neuronal loss. Recommendations about clinical management are largely based upon expert opinion since randomized controlled trials in DLB are few. Substantial progress has been made since the previous report in the detection and recognition of DLB as a common and important clinical disorder. During that period it has been incorporated into DSM-5, as major neurocognitive disorder with Lewy bodies. There remains a pressing need to understand the underlying neurobiology and pathophysiology of DLB, to develop and deliver clinical trials with both symptomatic and disease-modifying agents, and to help patients and carers worldwide to inform themselves about the disease, its prognosis, best available treatments, ongoing research, and how to get adequate support.
Miller BL, Boeve BF (Eds). Behavioral Neurology of Dementia, Cambridge: Cambridge University Press, 2009.
Grant support as an investigator in clinical trials funded by GE Healthcare, 2012-present; FORUM Pharmaceuticals, 2015-2016; C2N Diagnostics, 2016; Axovant, 2016-present.
NIH: P50 AG016574 (2009-present), U01 AG006786 (2009- present), RO1 AG032306 (2010-present), RO1 AG041797 (2012- present), UO1 AG045390 (2014-present), and U54 NS092089 (2014-present)
Mangurian Foundation, 2011-present Little Family Foundation, 2015-present
Novartis, invited speaker honorarium and travel, Tokyo, Japan, Oct 2016
Editorial board member: Acta Neuropathologica, Brain, Brain Pathology, Neuropathology and Applied Neurobiology, Annals of Neurology, Neuropathology; Editor: International Journal of Clinical and Experimental Pathology, American Journal of Neurodegenerative Disease.
P50AG016574 (Core Leader); P50NS072187 (Center Director); P01NS084974 (Project Leader); P01AG003949 (Core Leader)
(1) Danish Research Institute of Translational Neuroscience, Aarhus University
(1) Medical Review Co. Ltd., speaker honoraria (2) H Lundbeck A/S, travel (3) 2016 Alzheimer's Association International Conference, travel (4) American Academy of Neurology, travel & speaker honoraria (5) Michael J Fox Foundation, travel (6) International Society for Neurochemistry, travel (7) International Parkinson & Movement Disorder Society, travel (8) NHMRC National Institute for Dementia Research, travel (9) 10th International Conference on Frontotemporal Dementia, travel (10) Queensland Brain Institute, travel (11) 5th International Congress on Multiple System Atrophy, travel (12) International Conference on Dementia with Lewy Bodies, travel
(1) Acta Neuropathologica, editorial board member, 2006- (2) Journal of Neural Transmission, editorial board member, 2007- (3) Journal of Parkinson's disease, editorial board member, 2010- (4) Translational Neuroscience, editorial board member, 2011- (5) Neuropathology & Applied Neurobiology, editorial board member, 2012- (6) Neurobiology of Disease, editorial board member, 2014- (7) IBRO reports, editorial board member, 2016-
(1) Atlas of the developing mouse brain E17.5 P0 P6, Elsevier, 2006 (2) Non- dopamine lesions in Parkinson?s disease, Oxford University Press, 2011 (3) The human nervous system, Academic Press, 1990, 2003 & 2012 (4) The rat nervous system, Academic Press, 1995 & 2004
(1) National Health & Medical Research Council of Australia, 1079679, 1037746, 1095127, 1103757, Principal Investigator, 2013-2020
(1) Michael J Fox Foundation (2) Shake It Up Australia (3) Parkinson's New South Wales (4) Multiple System Atrophy Coalition (5) Motor Neuron Disease Research Institute
(1) Cochlear (Australian hearing implant company) (2) NIB Holdings (Australian & New Zealand health insurance company
(1) Lewy body disease Association- non-profit entity (2) Lewy body Society - non-profit entity (3)Cognition Advisory Group (Michael J Fox Foundation) - non-profit entity
(1) National Institute of Health Research (NIHR), United Kingdom, Newcastle Biomedical Research Unit based at Newcastle upon Tyne Hospitals NHS Foundation Trust/Newcastle University, and an NIHR Biomedical Research Centre award to Newcastle University, support for study (2012-2017) (2)National Institute of Health Research (NIHR) Programme Grant Diamond Lewy, SHAPED and PROVIDE studies, no relationship to current study.
(1) Wellcome Trust, Intermediate Clinical Fellowship (2010-2014), support to last author (Taylor) (2) Alzheimer's Research UK (2011-2014), no relationship to present study (3) Alzheimer's Society UK (2015-2018), no relationship to present study
Commercial - Pfizer, Teva Pharmaceuticals, Avanir Pharmaceuticals, Merck & Co., Lundbeck Inc., UCB, Bristol- Myers Squib Company, Novartis, Clintrex, Theravance, Medivation Non-profit - CHDI, ADCS
Serves on Editorial Board of Movement Disorders Journal and Journal of Parkinson's Disease
NINDS, P50 NS053488, Investigator, 2007- NINDS, R01NS065087, Investigator, 2009-2012 NIA, RO1AG031348, Investigator, 2008- NIA, U19 AG10483-22, DSMB Chair, 2013- Department of Veterans Affairs
Michael J. Fox Foundation for Parkinson's Research, PI, 2009-2011 Michael J. Fox Foundation for Parkinson's Research, PI, 2011- Michael J. Fox Foundation for Parkinson's Research, Investigator, 2011-
Licensing fees from the University of Pennsylvania for licensing of Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease.
Phase 2 double-blind, placebo-controlled trial of Nilotinib in patients with mild to moderate AD. PI: R. Scott Turner, MD (Sponsor: Alzheimer Drug Discovery Foundation) 2016-present; Role: Chair, DSMB Glutamatergic Dysfunction in Cognitive Aging: Riluzole in Mild Alzheimer Disease. PI: Ana Pereira, MD (Sponsor: Alzheimer Drug Discovery Foundation) 2012-present; Role: Chair, DSMB A Preliminary Study of Carvedilol for the treatment of Alzheimer?s Disease (R01 AG00035546) PI: Paul Rosenberg, MD. (Sponsor: National Institute on Aging) 2011-present, Role: Member, DSMB
Alzheimer disease and associated disorders, editorial board, 2005- present Neurodegenerative disease management, editorial board, 2012-present
1/ commercial entities: serving on an advisory board for Acadia, Lundbeck, Bristol-Myer Squibb, Otusaka and Napp pharmaceutical companies and Synexus clinical trial recruitment company. 2/Non profit: Served on several advisory boards for the Wellcome trust.
Commercial entity - Lundbeck, honorarium Commercial entity - Acadia, honorarium Commercial entity - Bristol Myer Squibb, honorarium Commercial entity - Napp, honorarium Commercial entity - Bial, honorarium
Non-commercial entity - Professor of Age-Related Diseases king's college London Non-commercial entity - Director of Research, Alzheimer's Society until April 2013
Commercial entity - Lundbeck Advisory Boards Commercial entity - Acadia Advisory board and general consultancy Commercial entity - Bristol Myers Squibb Advisory Boards Commercial entity - Synexus Advisory Board and general consultancy
Commercial entity - Lundbeck, Investigator led clinical trials Commercial entity - ACADIA, Investigator supported clinical trials
NIHR Programme Grant (UK) Lead PI 2010 - 2015 NIHR Infrastructure 2012 - 2017
Alzheimer's Society Alzheimer Research UK BUPA Foundation European Union Parkinson's Society Research into Ageing Edmund J Safra Foundation Wellcome Trust
1) funding for travel from MagQu Co. Ltd. 2) Funding for travel and speaker honorarium from the National Cheng Kung University of Taiwan; funding for travel and speaker honorarium from the Human Amyloid Imaging conference organizers.
I have been employed since 1997 solely with the non- profit organizations Sun Health Research Institute and Banner Health.
Commercial entities: Avid Radiopharmaceuticals; Navidea Biopharmaceuticals
(1) National Institute on Aging P30 AG19610, 2001 - present (2) National Institute of Neurological Disorders and Stroke,U24 NS072026, 2011 - present
Michael J. Fox Foundation for Parkinson?s Research, several separate grants or programs for non-profit research, 2006 - present
(1)G?riatrie et Psychologie Neuropsychiatrie du Vieillissement (GPNV), journal editor, since 2015, (2) Behavioural Neurology, associate editor, since 2014, (3) Biomed Research International, associate editor, since 2014.
(1) Projet hospitalier de Recherche Clinique,IDRCB 2012-A00992-4, principal investigator, 2013-2016.
Research support from Axovant sciences and Chase Pharmaceuticals
NIH principal investigator R01 NS070856 2010-1017; co- investigator P01 NS015655 (2008-2013), P50 NS091856 (2013-2018); Department of Veterans Affairs Principal Investigator I21 RX001587 (2015- 2017), I01 RX001631 (2016-2020)
Cure Parkinson's Trust Oxford Parkinson's Disease Center World Parkinson's Congress
Teva/ H. Lundbeck A/S - Co-Inventor of Azilect (Rasagiline) in the use of treatment of olfactory deficits in PD or other conditions.
R21NS093993, NIH/NINDS 12253 Michael, J Fox Foundation R01NS096241, NIH via Northwestern University East Tennessee Foundation Cure Parkinson's Trust 30-40321-1, Michael J Fox Foundation Cook Foundation
Acousort AB, Lund, 2010 to present ParkCell AB, 2009 to present
Acadia Pharmaceuticals: speaker honorarium at Movement Disorders Meeting in San Diego 2015
Henry Stewart publishers for online movement disorders resource Oxford University Press for Editing
BIAL - payment to University (not personal)in 2015 Benevolent Bio - - payment to University (not personal)in 2016
A Biomedical Research Unit in Lewy Body Dementia. NIHR: 1st April 2012 - 31st March 2017; (Burn DJ, McKeith IG, O?Brien JT, Kirkwood TBL, Chinnery PF, Ford GA). Medical Research Council UK - Clinical Research Infrastructure award for PET/MRI (?4.7m) March 2014 - April 2015
Parkinson's UK: Visual symptoms in Parkinson?s disease and Parkinson?s disease dementia: Association with ocular and retinal pathology, visuo-perceptual deficits and impact on daily living and quality of life. Parkinson?s UK: November 2007- October 2010; (Archibald N, Mosimann UP, Clarke MP, Burn DJ). Predicting Dementia in Parkinson?s disease: A genotypic and phenotypic study (ICICLE-PD). Parkinson?s UK REF J0802, UK: October 2007 ? September 2012; (Burn DJ, Barker RA, Brooks DJ, O?Brien JT, McKeith IG, Chinnery PF, Owen AM, Brayne CEG, Robbins T, Sawcer S, Coleman S). The Parkinson?s Repository of Biomarkers and Networked Datasets (PROBAND) programme: A UK national clinical consortium linking novel biomarker research to clinical expression, and progression rates, in Parkinson?s disease. Parkinson?s UK: 2011-2015; (Grosset D, Burn DJ, Barker RA, Ben-Shlomo Y, Bajaj N, Hardy J, Wood NW, Morris HR). Apomorphine: A modifier of amyloid deposition in Parkinson?s disease? Parkinson?s UK REF K-1101: October 2011 - April 2012;(Burn DJ, Revesz T, Lees AJ). Michael J Fox Foundation Clinical trial to compare cognitive scales. Michael J Fox Foundation: 1st October 2011 - 30th September 2016; (Burn DJ, Weintraub D). Predicting cognitive profiles in Parkinson?s disease: A multimodal approach. Michael J Fox Foundation: 1st November 2011 - 31st October 2013; (Burn DJ, Rochester L, O?Brien JT, Coleman SY, Baker MR).
Serve on a scientific advisory board for the Michael J. Fox Foundation for special projects
Patents pending on: (1) Viral-mediated gene delivery of the progranulin gene as a therapeutic for frontotemporal dementia (2) Use of the discovery of 8 plasma proteins as biomarkers for diagnostic confirmation of Parkinson's Disease diagnosis
(1) NIH-NINDS RO1 NS082265 (PI, 2013-2018) (2) NIH-NINDS UO1 NS082134 (PI, 2012-2017) (3) NIH-NINDS P50 NS053488 (Project leader, 2012-2017)
(1) Burroughs Wellcome Fund (private foundation, received Career Award for Medical Scientists) (2) Alzheimer's Association/Michael J. Fox Foundation
(1)PlosONE, Academic Editor, 2010-present (2)Movement Disorders, Editorial Board Member, 2013- 2015 (3) npj Parkinson's Disease, Editorial Board Member, 2015- present
(1) Rehabilitation Research and Development Service of the Department of Veterans Affairs, RX-B1097-I, PI, 2013- present (2) NINDS, CSP#468F, Site Investigator, 2010-2015 (3) NIH, U01-NS094340, Co-PI, 2015-present
1. Since 2005 member of the Editorial Board of Protein & Peptide Letters (http://www.bentham.org/ppl/EBM.htm). 2. Since 2005 member of the Editorial Board of American Journal of Alzheimer?s disease and Other Dementia (http://atgstg01.sagepub.com/journalsProdEditBoards.nav? prodId=Journal201798). 3. Since 2008 member of the Editorial Board of The Open Biology Journal (http://www.bentham.org/open/tobioj/EBM.htm).
1. Diagnostic Agent for Parkinson?s disease, British Patent Application No. 0916264.5, filed 16th September 2009. O.M.A. El-Agnaf.
$175,000 (Co-PI with Dr. Michael G. Schlossmacher, University of Ottawa) Michael J. Fox Foundation for Parkinson?s Research, USA. ?Validation of CSF alpha- synuclein as a biomarker for Parkinson?s disease?. 2008- 2010.
Payments for service agreements to University of British Columbia or University of California, San Diego 1. Commercial; Genentech: Diagnostic Monitoring Committee 2. Commercial Eisai LTD: Data Safety Monitoring Board 3. Commercial Tau Rx: Scientific Advisory Board 4. Not for Profit: Tau Consortium: Scientific Advisory Board
1. Not for Profit: Tau Consortium Investigator Meetings (travel expenses) 2. Not for Profit: Alzheimer Society of Canada 2015 (travel expenses) 4. Not for Profit: US Alzheimer Association 2015, 2016 (travel expenses) 4. Not for Profit: Brain Canada 2014 (travel expenses)
Journal of Prevention of Alzheimer's Disease 2014-present (editorial board) Alzheimer's & Dementia Translational Research and Clinical Interventions 2014-present (editorial board)
Royalties from the book Atlas of Alzheimer?s Disease (2007) Informa Health London
Director of the Alzheimer Disease Cooperative Study (April 2016-present)which has undertaken clinical trials with study sponsors AC Immune and QR Pharma (2016-present). Co- investigator on sponsored clinical trials at the UBC Alzheimer Clinic including Tau Rx, Roche, and NIA/Lilly.
1. Canadian Institutes of Health Research CIHR # 287674 (2013-18)role co Principal Investigator, 2. CIHR Consortium for Neurodegeneration and Aging # 137794,co Principal Investigator and Member Research Executive(2014-19)Grant 3. CIHR Canadian Pipeline for AD Therapeutics 2015 Nominated Principal Investigator (2015-16) 4. CIHR and Weston Foundation Intranasal Oxytocin for FTD Co-Investigator (2016-2020) 5. University of California Cure AD: Salsalate in AD Co- Investigator (2016-2018) 6. Brain Canada MIRI: Preclinical Development
(1) National Institute on Aging, AGO 5131, PI, 2009 - 2017, (2) National Instittue on Aging, AG10483, CoI, 2012-14, AGO36528, CoI, 2008-present (3) State of California, Department of Health Services, 2009-present (4) California Institute for Regenerative Medicine
(1) Michael J Fox Foundation (2) Alzheimer's Drug Discovery Foundation
1) Movement Disorder Society (travel, honoraria), 2) American Academy of Neurology (travel), 3) MedEdicus (honoraria), 4) Haymarket (honoraria)
1) Movement Disorders Journal, Editorial board member, 2015-present; 2) Journal of Clinical Movement Disorders, Editorial board member, 2014- present
Michael J. Fox Foundation, Parkinson's Disease Foundation, Consolidated Anti-Aging, National Parkinson Foundation, CHDI, HDSA
(1) TauRx FTD multicenter study (2) Lilly multicenter study (3) Biogen multicenter study (4) Axovant multicenter study
(1) NIA P50AG16574 coinvestigator ADRC; (2) NIA U24AG26395 Site PI LOAD study; (3) NIA U01AG24904 Site PI ADNI; (4) NIA R01AG06656 Coinvestigator
Lundbeck, Travel to meeting, Eli Lilly, Travel to meeting, Bristol-Myer Squibb, Travel to meeting, vTv Therapeutics, Travel to meeting, Axovant, Travel to meeting, Roche, Travel to meeting, New York City Department of Health and Mental Hygiene, Honorarium.
Abbvie, AstraZeneca Axovant, Bristol-Myer Squibb C2N Diagnostics, Eisai, Eli Lilly, Forum, Genentech, Lundbeck, Pfizer, Roche, TauRx, vTv Therapeutics.
NIH/NINDS U01NS100600, PI, 2016-2017 New York State DOH C031425, PI, 2016-107 NIH/NIA P50AG008702, coI, 2015-2017 NIH/NIA U01AG051412, coI, 2015-2017 NIH/NINDS R01NS083976, coI, 2015-2017 NIH/NIA U01AG016976, coI, 2015-2017 NIH/NIA U01AG023749, coI, 2015-2017
Alzheimer's Drug Discovery Foundation Henry Panasci Foundation Alzheimer's Association Lewy Body Disease Association
Data safety monitoring board member for Takeda Global Research & Development Center, Inc., Pfizer Inc. and Janssen Alzheimer Immunotherapy
R01 AG040042 (PI); 2011-2016, P50AG044170/P2(PI); 2012- 2017;
Minnesota Partnership for Biotechnology and Medical Genomics; 2013-2015
Pfizer speaker's bureau, 2003-2008 Forest Speaker's bureau 2003-2007 Novartis speaker's bureau 2007-2009 Johnson & Johnson speaker's bureau 2003-2007
1. TauRx Therapeutics TauRx 10/8/2013 ? 10/7//2016 1.2 cal. A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotemporal Dementia (bvFTD). 2. Navidea Biopharmaceuticals 6/1/15 - 5/30/17 1.2 calendar. NAV4-02: A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral β-Amyloid When Compared With Postmortem Histopathology. 3. NOPRODALZ0001 (D. Kaufer, PI) 05/15/15 ? 06/30/17 4.26 calendar Janssen Research & Development, LLC $259,877.36 A Randomized, Cross-Over Controlled Feasibility and Validation Study of a Self-Administered Memory Screening Test with Automated Reporting (SAMSTAR) in Healthy Elderly and Mild Cognitive Impairment Subjects To evaluate the psychometric properties (criterion validity) of a Self-Administered Memory Screening Test with Automated Reporting (SAMSTAR) adapted from the Rey Auditory Verbal Learning Test (RAVLT) in subjects aged 55 to 84 years who are receiving healthcare in primary care and/or neurology practice settings against a standard version of the RAVLT test, administered by an examiner under the same conditions.
5-R01-AG050602-01-02 (S. Zimmerman, PI) 09/01/15-05/31/20 0.24 calendar NIA $400,735 Addressing Behavior and Mood in Assisted Living: Organizational Characteristics Related to the Use of Antipsychotic and Psychotropic Medications and Alternative Practices. This project will describe the range of antipsychotic and other psychotropic medication prescribing in assisted living, as well as how prescribing varies by characteristics of the assisted living organization, information about potentially inappropriate prescribing, and the feasibility of implementing non-pharmacological alternatives to care. The advisory board will help disseminate the related findings to inform practice and policy. *1-R01-NS093842-01A1 (P. Yap, PI) 03/01/16-02/28/19 0.24 calendar NIH NINDS $247,501 Robust White Matter Morphometry with Small Databases The goal of this project is to create novel statistical computational tools for increased robustness in the statistical analysis of diffusion MRI data, particularly in situations where samples are noisy, limited, and exhibit complex shape variations. *1-RF1-AG053867-01A1 (D. Shen, PI) 09/30/16-06/30/21 0.6 calendar NIA/NIH $318,233 Analyzing Large-Scale Neuroimaging Data in Alzheimer's Disease. This project aims to develop novel deep multi-layer groupwise registration methods for effective, efficient and simultaneous registration of all brain images with possibly large anatomical and appearance differences. *1U01NS100610-01 (D. Kaufer, Site PI) 09/30/16-07/31/21 0.36 calendar CCF $62,360 Dementia with Lew Bodies Consortium The goal of this project is to provide longitudinal cognitive, motor and behavioral evaluations as suggested by the Dementia with Lew Body (DLB) module used for the National Institute on Aging Alzheimer?s Disease Research Centers. 5-R01-EB008374-05-07 (Shen, D.) 05/1/15-01/31/19 0.46 calendar NIBIB/NIH $297,138 4D Software Tools for Longitudinal Prediction of Brain Disease The goal of this renewal project is to create a set of innovative 4D software tools that are dedicated to more effective early diagnosis and prediction of brain disorders with longitudinal data. These tools will allow elucidating subtle abnormal changes that would be otherwise left undetected with existing tools. 1R01AG049371-01A1 (Subaward) (Shen) 09/01/15-04/30/20 0.6 calendar University of Texas at Arlington/NIH $135,819 Imaging Genomics Based Brain Disease Prediction The goal of this project is to work with UTA on developing a novel sparse learning based system biology framework for analysis of genome-wide association results across a large number of the structural and functional phenotypes derived from MRI and PET scans of the whole brain, as well as for developing the new structured sparsity-inducing norms based multi-dimensional data integration methods to identify the biomarkers from heterogeneous imaging genomic data for MCI conversion prediction. 5-R01-AG041721-04-051 (D. Shen, PI) 08/01/12 ? 03/31/20 0.18 calendar NIH $240,589 Quantifying Brain Abnormality by Multimodality Neuroimage Analysis This grant project will employ multiple regression statistical methodology to develop a high-level quantitative analytical platform for detecting quantitative individual differences in brain pathology. U54 RFA-TR-13-002 (A. Boxer, UCSF, PI) 09/01/14 ? 07/31/19 0.60 calendar NIH $205,200 Rare Diseases Clinical Research Consorita (RDCRC) for Rare Diseases Clinical Research Network This grant project will establish a multicenter clinical consortium to study clinical characteristics and biomarkers for tauopathy-spectrum disorders (frontotemporal degeneration, corticobasal degeneration, and progressive supranuclear palsy)
1. Guardian Angel Thrift Fund 2. National Football League Players Association
Special Emphasis Panels for grant review of NIH and CDC applications; External Advisory Committees for Alzheimer's disease centers: UCI, USC, U Kansas, Mt Sinai(NY), Boston U and Biocard study at JHU
Univ of Florida, Gainesville. travel and lodging to give a talk on Alzheimer's disease. Feb, 2012. Travel for talk at Changchun University, China,2015 Travel for talk at Dongzhimen Hospital, Beijing, China 2016
Editorial board member 2002-present: Alzheimer's Disease and Associated Disorders (no pay) Senior Associate Editor, Alzheimer's and Dementia, 2015 - present. (no pay)
1) External Advisory committee: UC Irvine ADRC 2)External Advisory committee: Mt Sinai ADRC 3) External Advisory committee:University of Kansas ADRC 4) Scientific Advisory Committee: Biocard Study, JHU 5) External advisory committee Boston U. ADRC 6)External Advisory Committee, USC ADRC
National Institute on Aging, U01 AG016976,1999-present, PI as obtained through the University of Washington Co-investigator, Alzheimer's Disease Genetics Consortium (NIA grant; G. Schellenberg, U Penn, PI)
Alzheimer's Association, Lumbar puncture survey study LPSS 11-219245 Principal Investigator
An editorial board member of Laboratory Investigation, Neurorehabilitation and Neural Repair, NeuroSignals, Neuron, Experimental Neurology, Science Magazine
NIH/NIA P30-AG 009215-19 (5/1/05-4/30/2010), Core B, Project 4, Project 1 (salary support) direct
1. 9/30/16 ? 7/31/21, NINDS, UO1 NS100610, ?Dementia with Lewy Bodies Consortium?, Role: PI, 7/15/09-present 2. 9/30/15 - 8/31/20, NIA, 1RF1AG051495-01, ?Central and Peripheral Roles of TREM2 in Alzheimer?s Disease?, Role: Co-Investigator 3. NINDS, P50 NS062684-01, Clinical Core Director until 12/31/13, Consultant 1/1/14 to present
1. 1/1/17 ? 7/31/21, Lewy Body Dementia Association, ?Dementia with Lewy Bodies Consortium Annual Meeting?, Role: PI 2. 8/1/14 - 7/31/17, Alzheimer?s Drug Discovery Foundation, ?Rasagiline Rescue in Alzheimer?s Disease Clinical Trial?, Role: Site PI 3. 8/1/14 - 7/31/17, Alzheimer?s Drug Discovery Foundation, ?Rasagiline Rescue in Alzheimer?s Disease Clinical Trial?, Role: Site PI 4. 3/1/16 ? 2/28/18, Alzheimer?s Association, ?Neuroimaging, Amyloid, and Cognitive Function in Down Syndrome?, Role: Co-Investigator 5. 2/1/2016 ? 2/1/17, Michael J Fox Foundation. ?Pathology Core ? The Parkinson?s Progression Markers Initiative (PPMI)?, Role: PI.
(1)Movement Disorders, Editorial Board, 2012-2014 (2)Journal of Neurology, Editorial Board, 2013- (3)NPJ Parkinson's Disease, Editorial Board, 2015- (4)Journal of Clinical Neuroscience, Editorial Board, 2014-
(1)NHMRC, 1085404, Co-Investigator, 2015-2019 (2)NHMRC, 1044791, Lead Investigator, 2014-2016 (3)NHMRC, 1060992, Co-Investigator, 2015-2018 (4)NHMRC, 1003007, Practitioner Fellowship, 2011-2015 (5)ARC, DP110104202, Co-Investigator, 2011-2015
(1)Parkinson's NSW (2)Alzheimer's Australia (3)Michael J Fox Foundation
On Med Sci committees for AFTD, LBDA, Alzheimer's Association (Delaware Valley Chapter). All for over 5 years
Am J of Alz Dis and Other Disorders (Editor-in-Chief) over 5 years, J Neuropathol Exp Neurol (Editorial Board)
My employer has received compensation for clinical trials from the following studies CFL is involved in: (UCB Pharma, Novartis, ELAN, Danone, Janssen)
Potamkin Foundation and the Newmann Foundation have supported research conducted by CFL and Drexel University College of Medicine
(1) GE Heathcare Advisory Panel, UCB Advisory Panel, Novartis Advisory Panel
(1) Current Pharmacogenomics and Personalized Medicine, associate editor, four years
PRIMARY INVENTOR on the following: 1. Determination of Single Nucleotide Polymorphisms Useful to Predict Response for Rasagiline. Taiwan, Province of China. TW 104110766. 2014/04/01. Patent Status: Pending Funding Sources: Teva Neuroscience Inc. - 6197360335 2. Determination of Single Nucleotide Polymorphisms Useful to Predict Response for Rasagiline. United States. US 14/674,606. 2014/04/01. Patent Status: Pending Funding Sources: Teva Neuroscience Inc. - 61973603 3. Determination of Single Nucleotide Polymorphisms Useful to Predict Response for Rasagiline. United States. PCT/US15/023618. 2014/04/01. Patent Status: Pending Funding Sources: Teva Neuroscience Inc. - 61973603 4. Determination of Single Nucleotide Polymorphisms Useful to Predict Response for Rasagiline. Argentina. AR 20150101010. 2014/04/01. Patent Status: Pending Funding Sources: Teva Neuroscience Inc. - 61973603
(1) Psychopharmacogenetics: Genetic Factors Influencing the Kinetics and Dynamics of Psychotropic Drugs - Of Genes & Drugs: Genetic Determinants of Adverse Drug Reactions, Henry Stewart Talks, 2006, receipt of royalties
(1) Canadian Institutes of Health Research, Clinician Scientist Award, principal investigator, four years (2) Canadian Institutes of Health Research, Operating grant, principal investigator, two years (3) Ministry of Research, Innovation and Science, principal investigator, 5 years (4) Weston Brain Institute, Operating grant, principal investigator, three years (5) Washington University, Clinical trial, site principal investigator, four years (6) Sunnybrook AFP Innovation Fund, grant, principal investigator (7) Ontario Brain Institute, operating grant, site principal investigator, five years
(1) Department of Medicine, Sunnybrook Health Sciences Centre (2) Sunnybrook Health Sciences Centre AFP Innovation Fund (3) Division of Neurology New Initiatives Program 2013
(1) Parkinson Society Canada, New Investigator Award (2) Consortium of Canadian Centres for Clinical Cognitive Research (3) Alzheimer's Drug Discovery Foundation (4) Brain Canada
presentations from GlaxoSmithKline, Orion Pharma, TEVA-Pharma and travel costs from TEVA-Pharma
TEVA-Pharma, Desitin, Boehringer Ingelheim, GE Healthcare; scientific collaborations with Roche, Bristol Myers Squibb, Ely Lilly, Covance and Biogen
BM is member of the executive steering committee of the Parkinson Progression Marker Initiative and the Systemic Synuclein Sampling Study of the Michael J. Fox Foundation for Parkinson?s Research and has received grants from the BMBF, EU, Parkinson Fonds Deutschland, Deutsche Parkinson Vereinigung, Michael J. Fox Foundation for Parkinson?s Research, Stifterverband f?r die deutsche Wissenschaft
(1) GE Healthcare, speaker honoraria (2) Lilly, speaker honoraria (3) Piramal, speaker honoraria
(1) Psychological Medicine, Editorial Board (2) International Psychogeriatrics, Deputy Editor (3) Australian & New Zealand Journal of Psychiatry, Editorial Board
(1) Parkinson?s Disease Society 01.10.2007-30.09.2010; (2) Sir Jules Thorn Charitable Trust, 01.02.2006- 31.01.2011; (3) DoH/Wellcome Trust, 01.06.2006-31.05.2011; (4) Medical Research Council, 01.11.2007-31.12.2013; (5) Parkinson's Disease Society, 01.02.2009-31.01.2014; (6) Member of the NIHR College of Senior Investigators, 01.04.2009-31.03.2014; (7) NIHR, 01.03.2010-28.02.2013; (8) Wellcome Trust Intermediate Fellowship, 01.05.2010- 30.04.2013; (9) NIHR-RfPB, 01.08.2010-31.07.2012. (10) The Food Standards Agency, 01.12.2010-31.07.2013. (11) BUPA/Alzheimer's Society, 01.12.2010-30.11.2012. (12) British Heart Foundation/The Stroke Association, 01.01.2011-31.12.2015. (13) HTA, 01.03.2011-30.04.2014. (14) Alzheimer's Research Trust, 01.03.2011-31.08.2012. (15) Cambridgeshire and Peterborough NHS Foundation Trust (fb NHS/NIHR), 01.02.2014-31.12.2018.
(1) Eisai Co.,Ltd., (2) Novartis Pharma K.K.,(3) Otsuka Pharmaceutical Co., Ltd. (4) GlaxoSmithKline K.K. (5) Sumitomo Dainippon Pharma Co.,Ltd. (6) Nihon Medi-Physics Co.,Ltd.
(1) JAPAN Agency for Medical Reserch and Development (AMED)
Axovant Sciences, Inc., Vice President, Medical and Scientific Communications, 2015-present
As part of my compensation as an employee of Axovant Sciences, I received stock options. In addition, two of my family members also work at Axovant Sciences and have received stock options as part of their compensation packages.
Editorial advisory board member: Parkinsonism and Related Disorders Molecular Neurodegeneration American Journal of Neurodegenerative Disease
(1) NINDS Udall Parkinson's Disease Research Center of Excellence P50 #NS072187; 2012-1017. (2)NINDS R01 NS078086; 2012-2017. (2)NIH U54 NS100693
Editorial Board of American Journal of Geriatric Psychiatry and International Journal Of Geriatric Psychiatry
Royalties for Oxford Textbook of Old Age Psychiatry, published by Oxford University Press, 2013
I have received FPCIT scans for investigator led research studies from GE Healthcare
American Journal of Medical Genetics, Neuropsychiatric Genetics. Associate editor, 2015-16 Editorial board member, 2011-current
1.NIH/NIA 1R01AG041797-01 Epidemiology of Familial Late-onset Alzheimer?s Disease, Site PI, 4/15/12-3/31/17. 2. VA Merit Review: Deep Sequencing in Schizophrenia in schizophrenia, BX002241, PI, 10/1/13?9/30/17 3. NIH/NIA P50 AG05136-22, Clinical Core, University of Washington Alzheimer?s Disease Research Center, co-investigator, 5/1/15-4/1/20 4.NIH/NIA U01 AG032984 Clinical Case-Control Genome Wide Association Studies, Alzheimer?s Disease Genetics Consortium, Co-PI, 4/1/09?3/31/20. 5. NACC Collaborative Project (2016-04) Plasma Biomarkers in Lewy Body Disease. Site PI, 9/1/16?8/31/18 6. Dementia with Lewy Bodies Consortium, NIH/NINDS 1 U01 NS100610- 01. Site PI, 11/01/16-10/31/21.
Department of Psychiatry and Behavioral Sciences, University of Washington
(1) Received speaker honoraria for GE sponsored educational events.
(1) Financial support from GE Healthcare for an investigator-led PhD project 'Late onset depression: clinical and imaging correlates of dopaminergic function'
(1) Legacy award research grant from North Essex Partnership University National Health Service Foundation Trust
Members of the DLB Consortium are listed at Neurology.org.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by NIHR Newcastle Biomedical Research Centre in Ageing and Long-Term Conditions.
This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.